Literature DB >> 22136373

Opioid activity of spinally selective analogues of N-naphthoyl-β-naltrexamine in HEK-293 cells and mice.

Morgan Le Naour1, Mary M Lunzer, Mike D Powers, Philip S Portoghese.   

Abstract

Using the selective mu-kappa agonist, N-naphthoyl-β-naltrexamine 1, as the prototype ligand, a series of closely related n class="Chemical">naphthalene analogues were synthesized to study the chemical space around the naphthalene moiety in an effort to evaluate how receptor selectivity is affected by chemical modification. Nine analogues (2-10) of compound 1 were synthesized and tested on HEK-293 cells expressing homomeric and heteromeric opioid receptors, and in the mouse tail-flick assay. It was found that a small change in structure produces profound changes in selectivity in this series. This is exemplified by the discovery that introduction of a 6-fluoro group transforms 1 from a selective mu-kappa heteromeric receptor agonist to a delta-preferring agonist 7. The in vivo studies reveal that many of the ligands are more potent spinally than supraspinally and devoid of tolerance.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22136373      PMCID: PMC3438918          DOI: 10.1021/jm200902v

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  23 in total

1.  G-protein-coupled receptor heterodimerization modulates receptor function.

Authors:  B A Jordan; L A Devi
Journal:  Nature       Date:  1999-06-17       Impact factor: 49.962

Review 2.  Dimerization: an emerging concept for G protein-coupled receptor ontogeny and function.

Authors:  Stephane Angers; Ali Salahpour; Michel Bouvier
Journal:  Annu Rev Pharmacol Toxicol       Date:  2002       Impact factor: 13.820

Review 3.  Is Galpha16 the optimal tool for fishing ligands of orphan G-protein-coupled receptors?

Authors:  E Kostenis
Journal:  Trends Pharmacol Sci       Date:  2001-11       Impact factor: 14.819

Review 4.  Selective naltrexone-derived opioid receptor antagonists.

Authors:  A E Takemori; P S Portoghese
Journal:  Annu Rev Pharmacol Toxicol       Date:  1992       Impact factor: 13.820

5.  Synthesis and opioid antagonist potencies of naltrexamine bivalent ligands with conformationally restricted spacers.

Authors:  P S Portoghese; G Ronsisvalle; D L Larson; A E Takemori
Journal:  J Med Chem       Date:  1986-09       Impact factor: 7.446

6.  The effect of various neurohumoral modulators on the activity of morphine and the narcotic antagonists in the tail-flick and phenylquinone tests.

Authors:  W L Dewey; L S Harris; J F Howes; J A Nuite
Journal:  J Pharmacol Exp Ther       Date:  1970-11       Impact factor: 4.030

7.  Design of peptidomimetic delta opioid receptor antagonists using the message-address concept.

Authors:  P S Portoghese; M Sultana; A E Takemori
Journal:  J Med Chem       Date:  1990-06       Impact factor: 7.446

8.  Binaltorphimine and nor-binaltorphimine, potent and selective kappa-opioid receptor antagonists.

Authors:  P S Portoghese; A W Lipkowski; A E Takemori
Journal:  Life Sci       Date:  1987-03-30       Impact factor: 5.037

9.  Narcotic antagonistic potency of bivalent ligands which contain beta-naltrexamine. Evidence for bridging between proximal recognition sites.

Authors:  M Erez; A E Takemori; P S Portoghese
Journal:  J Med Chem       Date:  1982-07       Impact factor: 7.446

10.  Intrathecal morphine in mice: a new technique.

Authors:  J L Hylden; G L Wilcox
Journal:  Eur J Pharmacol       Date:  1980-10-17       Impact factor: 4.432

View more
  5 in total

1.  Structure-Activity Relationship Studies of a Macrocyclic AGRP-Mimetic Scaffold c[Pro-Arg-Phe-Phe-Asn-Ala-Phe-DPro] Yield Potent and Selective Melanocortin-4 Receptor Antagonists and Melanocortin-5 Receptor Inverse Agonists That Increase Food Intake in Mice.

Authors:  Katlyn A Fleming; Mark D Ericson; Katie T Freeman; Danielle N Adank; Mary M Lunzer; Stacey L Wilber; Carrie Haskell-Luevano
Journal:  ACS Chem Neurosci       Date:  2018-02-13       Impact factor: 4.418

2.  Comparative Intracerebroventricular and Intrathecal Administration of a Nanomolar Macrocyclic Melanocortin Receptor Agonist MDE6-5-2c (c[Pro-His-DPhe-Arg-Trp-Dap-Ala-DPro]) Decreases Food Intake in Mice.

Authors:  Danielle N Adank; Mary M Lunzer; Mark D Ericson; Zoe M Koeperich; Stacey L Wilber; Katlyn A Fleming; Carrie Haskell-Luevano
Journal:  ACS Chem Neurosci       Date:  2020-09-10       Impact factor: 4.418

3.  Synthesis and characterization of a dual kappa-delta opioid receptor agonist analgesic blocking cocaine reward behavior.

Authors:  András Váradi; Gina F Marrone; Shainnel O Eans; Michelle L Ganno; Joan J Subrath; Valerie Le Rouzic; Amanda Hunkele; Gavril W Pasternak; Jay P McLaughlin; Susruta Majumdar
Journal:  ACS Chem Neurosci       Date:  2015-09-14       Impact factor: 4.418

4.  Comparative in Vivo Investigation of Intrathecal and Intracerebroventricular Administration with Melanocortin Ligands MTII and AGRP into Mice.

Authors:  Danielle N Adank; Mary M Lunzer; Cody J Lensing; Stacey L Wilber; Amy M Gancarz; Carrie Haskell-Luevano
Journal:  ACS Chem Neurosci       Date:  2017-10-19       Impact factor: 4.418

5.  Putative kappa opioid heteromers as targets for developing analgesics free of adverse effects.

Authors:  Morgan Le Naour; Mary M Lunzer; Michael D Powers; Alexander E Kalyuzhny; Michael A Benneyworth; Mark J Thomas; Philip S Portoghese
Journal:  J Med Chem       Date:  2014-07-18       Impact factor: 7.446

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.